CompanyGraph
4D Molecular Therapeutics, Inc.
FDMT · United States
4dmoleculartherapeutics.comFinancials as of FY2025
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
574.52MUSDvs all stocks (USD)
Revenue (TTM)
88.24MUSDvs all stocks (USD)
Profit Margin
-182.34%vs Biotechnology peers
Beta
2.69xvs all stocks
52-Week Change
159.19%vs all stocks
Market Capitalization
574.52MUSDvs all stocks (USD)
Enterprise Value
196.32MUSDvs all stocks (USD)
Forward P/E
-2.91xvs Biotechnology peers
Price to Sales (TTM)
6.42xvs Biotechnology peers
Price to Book (MRQ)
1.25xvs Biotechnology peers
Enterprise to Revenue
2.23xvs Biotechnology peers
Enterprise to EBITDA
-1.15xvs Biotechnology peers
Profit Margin
-182.34%vs Biotechnology peers
Operating Margin
-2416.15%vs Biotechnology peers
Return on Assets (TTM)
-21.43%vs Biotechnology peers
Return on Equity (TTM)
-34.92%vs Biotechnology peers
Revenue (TTM)
88.24MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.45USDUpdated Jul 18, 2026Quarterly Revenue Growth
21664.30%vs Biotechnology peers
Gross Profit (TTM)
-128.53MUSDvs all stocks (USD)
EBITDA (TTM)
-171.43MUSDvs all stocks (USD)
Net Income (TTM)
-160.90MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
21664.29%vs Biotechnology peers
Operating Cash Flow (TTM)
-129.45MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-69.36MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
85.21MUSDFY2025 · Dec 31, 2025Operating Income
-159.55MUSDvs all stocks (USD)
Pre-tax Income
-140.11MUSDFY2025 · Dec 31, 2025Net Income
-140.11MUSDFY2025 · Dec 31, 2025EBIT
-159.55MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-151.92MUSDFY2025 · Dec 31, 2025Research & Development
195.70MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
49.06MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
19.48MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-140.11MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-112.02MUSDFY2025 · Dec 31, 2025Free Cash Flow
-112.56MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
60.24MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-140.11MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
7.63MUSDFY2025 · Dec 31, 2025Stock-based Compensation
22.02MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
6.77MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-8.33MUSDFY2025 · Dec 31, 2025Capital Expenditures
-536.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-442.82MUSDFY2025 · Dec 31, 2025Sale of Investments
350.38MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-92.97MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
110.72MUSDFY2025 · Dec 31, 2025Shares Outstanding
52.27MSharesUpdated Jul 18, 2026Float Shares
38.95MSharesUpdated Jul 18, 2026Shares Short
13.31MSharesUpdated Jul 18, 2026Short Ratio
11.90daysvs all stocks
Short % of Shares Outstanding
29.42%vs all stocks
% Held by Insiders
3.21%vs all stocks
% Held by Institutions
98.36%vs all stocks
Total Cash (MRQ)
390.89MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
7.48USDUpdated Jul 18, 2026Total Debt (MRQ)
20.54MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0454xvs Biotechnology peers
Current Ratio (MRQ)
9.34xvs Biotechnology peers
Book Value per Share (MRQ)
8.64USDUpdated Jul 18, 2026Total Assets
566.71MUSDvs all stocks (USD)
Total Current Assets
413.13MUSDFY2025 · Dec 31, 2025Total Liabilities
61.05MUSDFY2025 · Dec 31, 2025Total Non-current Assets
153.58MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
17.06MUSDFY2025 · Dec 31, 2025Total Current Liabilities
43.98MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
60.24MUSDFY2025 · Dec 31, 2025Other Short-term Investments
342.41MUSDFY2025 · Dec 31, 2025Accounts Payable
11.16MUSDFY2025 · Dec 31, 2025Short-term Debt
5.59MUSDFY2025 · Dec 31, 2025Deferred Revenue
360.00KUSDFY2025 · Dec 31, 2025Long-term Debt
15.82MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
138.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
6.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-716.30MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
505.66MUSDvs all stocks (USD)
52-Week Low
4.14USDUpdated Jul 18, 202652-Week High
14.00USDUpdated Jul 18, 202652-Week Change
159.19%vs all stocks
Beta
2.69xvs all stocks
50-Day MA
10.32USDUpdated Jul 18, 2026200-Day MA
9.68USDUpdated Jul 18, 2026Avg 10-Day Volume
720.87KSharesUpdated Jul 18, 2026Avg 30-Day Volume
993.04KSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-2.57USDUpdated Jul 18, 2026Other Income / Expense
-37.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.66
Altman Z-Score 3.88: safe zoneNotable
Altman Z-Score: 3.88
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
ChemoCentryx Inc
Tier 1ProductionApproval-Gated PipelineRule
Zeria Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Hansen Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhuhai Rundu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Sunflower Great Health Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Aohua Photoelectricity Endoscope Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Orient Gene Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Prime Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
Careray Digital Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Sihuan Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow